5aa-OGP and CBD Compositions for Fracture Repair and Osteolysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bone fractures, osteolysis, and bone-related diseases are expensive, time-consuming, and have questionable effectiveness, with a need for safe and efficient therapeutic approaches to enhance fracture healing and prevent bone loss.

Innovation Solution

Pharmaceutical compositions comprising a pentapeptide (5aa-OGP) and a non-psychoactive cannabinoid (CBD) that act synergistically to stimulate osteoblast activity, inhibit osteoclast activity, and enhance bone formation and repair.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for bone fractures and bone-related diseases are used, then bone healing and repair can be achieved, but the treatments are expensive, time-consuming, and have questionable effectiveness

Engineering Contradiction:

Improveeffectiveness of bone treatmentVSAvoidtime required for bone healing

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the chemical parameters by using a specific peptide sequence (OGP) derived from histone H4 with precise amino acid composition, and combines it with CBD at optimized ratios to achieve enhanced bone healing effectiveness and accelerated repair timelines compared to conventional treatments

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite pharmaceutical composition combining two distinct active ingredients - the OGP peptide and CBD - that work synergistically together. This composite approach produces greater therapeutic effect than either component alone, addressing both effectiveness and time efficiency in bone treatment

Inventive Principle:

Principle #40Composite materials

2Reliability

If invasive procedures are used to treat at-risk fractures, then fracture healing can be enhanced, but the procedures are expensive and associated with morbidity

Engineering Contradiction:

Improvefracture healing enhancementVSAvoidmorbidity from invasive procedures

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The OGP peptide acts as a biological intermediary that mediates between the body's natural healing processes and the desired outcome of enhanced fracture repair. It stimulates osteoblast activity and bone formation through natural biological pathways, avoiding the need for invasive mechanical or surgical interventions while still achieving superior healing results

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The treatment leverages the body's own osteoblast cells and natural bone formation mechanisms, activated and enhanced by the OGP-CBD composition. This self-service approach allows the patient's own biological system to perform the healing work, eliminating the need for external invasive procedures and their associated risks

Inventive Principle:

Principle #25Self-service

3Reliability

If osteoclast activity is not inhibited, then bone resorption continues in osteolytic conditions, but without targeted inhibition bone loss progresses

Engineering Contradiction:

Improveprevention of bone lossVSAvoidbone resorption by osteoclasts

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful osteoclast-mediated bone resorption process into a beneficial outcome by using the OGP-CBD composition to modulate and inhibit osteoclast activity. This prevents the destructive bone loss while simultaneously promoting bone formation, effectively stopping the harmful process and replacing it with constructive bone regeneration

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250213644A1Compositions and methods for treatment of bone-related disease or disorder

Publication Date: 2025.07.03 GABET YANKEL

AI summary

The present invention provides pharmaceutical compositions and methods for use in accelerating bone repair and growth and attenuating inflammation-induced osteolysis. In particular, the present invention provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG for use in treating osteolysis. The present invention further provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG and CBD for use in accelerating bone repair and/or bone growth in a subject having a bone fracture.